The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures
DOI:
https://doi.org/10.17179/excli2026-9522Keywords:
depressive disorder, major (MDD), depressive disorder, treatment-resistant (TRD), schizophrenia (SCZ), inflammation, kynurenine (KYN), biomarkersAbstract
Chronic low-grade inflammation (LGI) is increasingly recognized as a biologically meaningful contributor to heterogeneity in major psychiatric disorders. The tryptophan (Trp)–kynurenine (KYN) metabolic pathway is a leading candidate mechanism because immune and stress-related signals can redirect Trp metabolism toward bioactive KYNs that influence glutamatergic signaling, redox balance, energetics, and immune feedback. In treatment-resistant depression and schizophrenia spectrum psychosis, this pathway is especially relevant because inflammatory burden often coexists with anhedonia, fatigue, cognitive dysfunction, and negative symptoms. Yet the literature remains difficult to integrate. Studies often rely on shallow biomarker panels, inconsistent inflammatory phenotyping, mixed matrices, and incomplete handling of major confounders, including smoking, adiposity, sleep disruption, infection timing, and medication exposure. Interpretation is further complicated by the kynurenic acid (KYNA) paradox and by central–peripheral discrepancies, as KYNA-related findings are strongly shaped by biological context and compartment, with blood measures often diverging from cerebrospinal fluid profiles and therefore not reliably reflecting central branch balance. This review therefore aimed to identify the Trp–KYN nodes most relevant to chronic LGI in psychiatry, synthesize clinical and preclinical evidence by disorder and symptom module, and define realistic near- and long-term research priorities. Here we highlight that Trp–KYN findings become more coherent when interpreted as context-dependent branch-balance signatures rather than standalone biomarkers. This framework can improve comparability, sharpen stratification, and support biomarker-enriched translational psychiatry. More broadly, it offers a practical model for linking immune biology to symptom dimensions across heterogeneous brain disorders.
Downloads
Published
How to Cite
License
Copyright (c) 2026 Masaru Tanaka, László Vécsei

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
